Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Slides:



Advertisements
Similar presentations
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
State of the Art in BRCA-Mutated Ovarian Cancer
Evolving Paradigms in the Management of HR-Positive Breast Cancer
Current Management and Future Options for Tardive Dyskinesia
New Psoriasis Treatments
Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Applying Biosimilars in Hematologic Cancers
Improving Survival in Glioblastoma Multiforme
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Advances in Managing Inhibitors in Patients With Hemophilia A
Progression After Cancer Immunotherapy in Advanced NSCLC
Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update
New Standards of Care in ALK-Translocated Advanced NSCLC
Mid-Year Hemophilia Update
Treating Transplant-Ineligible Patients With Multiple Myeloma
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Addressing Disease Burden in Asthma
Updates in Detection and Management of BCRPC
Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Next-Gen Psoriasis Therapies:
Advances in Multiple Myeloma
Evaluating Next-Generation BTK Inhibitors
Case Studies in Unresectable Hepatocellular Carcinoma
Hyperhidrosis Is Burdensome!
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Immunotherapy for cSCC
The JAK-STAT Pathway and Graft-vs-Host Disease
Optimizing Frontline Care for Older Patients With Multiple Myeloma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.
Advancing Care Across the Spectrum of Pancreatic Cancer
PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Personalizing Management in the Care of Patients With Advanced Sarcoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Updates in the Management of Acute Promyelocytic Leukemia
Getting to Grips With the Science of CGRP and Migraine
Advances in Immunotherapy for Peanut Allergy
Locally Advanced Lung Cancer
Guide to Atopic Dermatitis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
Patient Questions and Expert Answers in Psoriasis:
The Role of Maintenance Therapy in Multiple Myeloma
Evaluating BTK Inhibitors in CLL
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
The Psychiatrist's Role in Tardive Dyskinesia
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Novel Concepts in the Management of RCC
From Adjuvant to Metastatic in Melanoma
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Prioritizing Prevention of HPV-Related Disease
The Psychiatrist's Role in Tardive Dyskinesia
New Paradigms in M0 CRPC.
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Checkpoint Inhibitors in First-Line Advanced NSCLC
VKA Reversal and LVADs.
How to Select Therapy in Relapsed/Refractory CLL
CDK4/6 Inhibitors.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immune Checkpoint Inhibitors in Lung Cancer
Presentation transcript:

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Please note, this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Multiple Myeloma and Bone Disease

Diagnosing Bone Disease

Impact of Bone Disease

Pathophysiology of Bone Disease in MM

Bone-Modifying Agents

Myeloma IX Trial Study Design

Myeloma IX Trial Impact of ZA on Survival

Myeloma IX Trial Impact of ZA on SREs

Non-Inferiority Study of Denosumab vs ZA Study Design

Non-Inferiority Study of Denosumab vs ZA SREs and PFS

Key Treatment-Emergent Adverse Events

Reversibility of Bone Modifying Agents

ASCO and NCCN Guidelines for Treatment With BMAs

Treatment Duration With Bisphosphonates

Treatment Duration With Bisphosphonates (cont)

Managing AEs Induced by BMAs Expert Opinion

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)